This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ONC201

Oncoceutics, Inc.

Drug Names(s): ONC 201, ONC-201, TIC10, TIC 10

Description: ONC201 was originally identified in a screen for TRAIL-inducing compounds, and subsequently proposed to induce the TRAIL receptor, DR5, specifically in tumor cells. The TRAIL pathway is a pro-apoptotic signaling pathway. Subsequently, the company announced that ONC201 antagonizes dopamine receptor, DRD2, a member of the D2-like dopamine receptor subfamily in the G protein-coupled receptor (GPCR) superfamily.

Upon elucidating the chemical structure with a three-ring heterocycle and two substitutable basic amines, the company coined the name imipridones to represent a class of compounds derived from ONC201, including ONC6 and ONC212.


ONC201 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug